癸他滨
医学
克拉屈滨
内科学
骨髓增生异常综合症
累积发病率
养生
髓系白血病
阿糖胞苷
移植
肿瘤科
造血干细胞移植
骨髓
DNA甲基化
化学
基因表达
基因
生物化学
作者
Xiaowei Tong,Mengyuan Li,Jie Jin,Yi Li,Li Li,Zhenya Hong,Lifang Huang,Bin Xu,Fankai Meng,Xia Mao,Liang Huang,Wei Huang,Donghua Zhang
摘要
Abstract To reduce the risk of relapse after allogeneic hematopoietic stem cell transplantation (allo‐HSCT), there have been continuing efforts to optimize the conditioning regimens. Our study aimed to analyze the risk factors associated with the relapse of relapsed/refractory (R/R), high‐risk acute myeloid leukemia (AML) and high‐risk myelodysplastic syndrome (MDS) post‐transplant and the efficacy of a new conditioning regimen involving decitabine and cladribine. Clinical data of 125 patients with R/R AML, high‐risk AML and high‐risk MDS who underwent allo‐HSCT were collected. In addition, 35 patients with R/R AML, high‐risk AML and high‐risk MDS received treatment with a new conditioning regimen including decitabine and cladribine. Cox regression analysis was used to identify risk factors associated with OS, RFS and relapse. Among 125 patients who underwent allo‐HSCT, CR before allo‐HSCT and matched sibling donors were independent protective factors for OS. DNMT3A abnormality was an independent risk factor for both relapse and RFS. Among 35 patients who received a new conditioning regimen containing decitabine and cladribine, only six patients relapsed and 1‐year cumulative incidence of relapse was 11.7%. Moreover, this new regimen showed efficient MRD clearance early after allo‐HSCT. The combined decitabine‐ and cladribine‐based conditioning regimen showed a low relapse rate and a high survival without an increased incidence of GVHD or adverse effects and thus has potential for use in allo‐HSCT for R/R AML, high‐risk AML and high‐risk MDS.
科研通智能强力驱动
Strongly Powered by AbleSci AI